Alprazolam use in Australia and policy approaches: watch this space
IDRS Bulletin April 2012: Benzodiazepine update
Benzodiazepine-related mortality: illicit drugs discussion paper no. 1
Benzodiazepine dependence and psychopathology among heroin users in Sydney
NDARC Technical Report No. 50 (1997)
Benzodiazepine use among heroin users in Sydney: Transitions between routes of administration
NDARC Technical Report No. 35 (1996)
Manual for the Benzodiazepine Dependence Questionnaire (BDEPQ)
NDARC Technical Report No. 33 (1996)
Benzodiazepine use among heroin users in Sydney: Patterns, availability and preferences
NDARC Technical Report No. 27 (1995)
Alprazolam related deaths soar since 2009
Tuesday, 24 June 2014
The number of sudden or unnatural deaths involving the high potency anti-anxiety medication alprazolam (including Xanax) has increased dramatically since 2009, a study by the National Drug and Alcohol Research Centre at UNSW has shown.
Circumstances and toxicology of sudden or unnatural deaths involving alprazolam
There has been a great deal of clinical concern regarding alprazolam (Xanax) abuse, so much so that the Therapeutic Goods Administration reclassified the drug effective 1 February 2014 from Schedule 4 (prescription only medicine) to Schedule 8 (controlled drug).